JOURNAL of
ONCOLOGICAL
SCIENCES

ORIGINAL RESEARCH ARTICLE

Controversies in the efficacy of adjuvant chemotherapy in different epithelial ovarian carcinoma histologies
Received Date : 15 Jul 2019
Accepted Date : 08 Sep 2019
Available Online : 17 Sep 2019
Doi: 10.1016/j.jons.2019.09.002 - Article's Language: EN
J Oncol Sci 5 (2019) 96-99
This is an open access article under the CC BY-NC-ND license
ABSTRACT
Aim: In this retrospective study, the efficacy of adjuvant chemotherapy and its contribution to prognosis were investigated in patients diagnosed with different subgroups of ovarian carcinoma at stages 1e3. Material and Method: Epithelial ovarian carcinoma cases treated at Ankara Oncology Training and Research Hospital of Health Sciences University between January 2014 and May 2018 were retrospectively analyzed. Results: A total of 145 patients were diagnosed and treated for EOC during the study period. According to histopathological subgroups, serous EOC was the most common (84.8%), followed by endometrioid (6.6%), mucinous (4.8%) and clear cell types (3.8%). Local recurrence and distant recurrences were observed in 39 (43.8%) and 7 (7.9%) cases in the serous EOC group, respectively. The median follow-up was 39 months (10e217 months). Median survival was 91.4 months (58.9e123.9 months) in the whole group and 100.9 months in serous EOC. Median survival in mucinous EOC was 26.2 months, whereas median survival in endometrioid EOC and clear cell EOC were not reached. A statistically significant difference of survival was found between serous and mucinous types of tumors (p: 0.04. Conclusions: According to the results of this study examining the survival outcomes of epithelial ovarian cancer subtypes after chemotherapy, there was a statistically significant difference between the prognosis of different epithelial ovarian cancer cases after taxane and platinum-containing adjuvant chemotherapy. Mucinous type of tumors exhibited less overall survival compared to endometrioid and clear cell types which needs to be confirmed with prospective clinical trials.
KAYNAKLAR
  1. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology. 2011;43: 420e432. https://doi.org/10.1097/PAT.0b013e328348a6e7, 2011/07/01. [Crossref]  [PubMed] 
  2. Deborah K, Armstrong RDA, Bakkum-Gamez Jamie N. Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer; 2019. https://www.nccn. org/professionals/physician_gls/pdf/ovarian.pdf. Accessed June 13, 2019.
  3. Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008;109:370e376. https://doi.org/10.1016/ j.ygyno.2008.02.006, 2008/04/09. [Crossref]  [PubMed] 
  4. Zaino RJ, Brady MF, Lele SM, et al. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Cancer. 2011;117:554e562. https://doi.org/10.1002/cncr.25460, 2010/09/24. [Crossref]  [PubMed]  [PMC] 
  5. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040e1044. https:// doi.org/10.1200/JCO.2004.08.078, 2004/03/17.
  6. Bamias A, Psaltopoulou T, Sotiropoulou M, et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116:1462e1468. https://doi.org/10.1002/cncr.24915, 2010/01/29. [Crossref]  [PubMed] 
  7. Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Canc. 2008;8:252. https://doi.org/ 10.1186/1471-2407-8-252, 2008/09/03. [Crossref]  [PubMed]  [PMC] 
  8. Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331e334. https://doi.org/10.1016/j.ygyno.2009.02.010, 2009/03/12. [Crossref]  [PubMed] 
  9. Sato S, Itamochi H, Kigawa J, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009;100:546e551. https://doi.org/10.1111/j.1349-7006.2008.01065.x, 2009/01/22. [Crossref]  [PubMed] 
  10. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480. https:// doi.org/10.1016/j.ajog.2011.06.049. e481-488. 2011/08/25.
  11. Karabuk E, Kose MF, Hizli D, et al. Comparison of advanced stage mucinous epithelial ovarian cancer and serous epithelial ovarian cancer with regard to chemosensitivity and survival outcome: a matched case-control study. J Gynecol Oncol. 2013;24:160e166. https://doi.org/10.3802/jgo.2013.24.2.160, 2013/05/09. [Crossref]  [PubMed]  [PMC] 
  12. Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 2010;21:2377e2381. https://doi.org/10.1093/annonc/mdq257, 2010/05/25. [Crossref]  [PubMed]